Episentec will present the Label-Enhanced SPR concept at the Biacore™ User Meeting in Lyon, France, 2nd July 2015. Looking forward to meeting many French SPR users and to seeing the beautiful city of Lyon. For any information prior to the meeting, please contact us at sales@episentum.com.
Take the opportunity to meet with Episentec at the “Next-Generation Antibodies and Protein Analysis: Tools & Technologies” conference in Gent, Belgium, 15-16 June 2015. We will present a poster showing how Label-Enhanced SPR improves the detectability and widens the dynamic range in protein and antibody analysis using Biacore™ instruments.
We will also spend 17 June in the Gent area, so if you’re interested in Label-Enhanced SPR and if you’re site is not too far from Gent, please contact us and we’ll arrange a meeting!
Please contact us at sales@episentum.com for any enquiries.
Label-Enhanced SPR is already a well-established tool that improves the detectability of small molecules in SPR analysis 100-fold. Our new Application Note 23 shows how also the detectability of antibodies can be improved 100-fold. The key feature here is not the enhanced sensitivity but the enhanced specificity, or in other words, the elimination of signal contributions from non-specific binding of undefined sample substances.
Please check out our Application Notes page for more info or order the new document directly from sales@episentum.com.
We have developed a new, improved version of the EpiGrammer™ software for Label-Enhanced SPR, and celebrate this with a special offer:
A free 3-month EpiGrammer trial license to all new Episentec™ dye reagent customers in April 2015.
EpiGrammer software is used for calculating enhanced sensorgrams based on our proprietary Label-Enhanced SPR technology:
News in version 2.1:
Please contact sales@episentum.com for any enquiries or to place an order.
The CEO of Episentec, Anders Hanning, has been invited to give a presentation about Label-Enhanced SPR at the MRC Laboratory of Molecular Biology (LMB), Cambridge, UK. The LMB, sometimes nicknamed ‘The Nobel Prize Factory’, has received 10 Nobel prizes shared amongst 14 individuals, including names such as Watson & Crick (DNA structure), Milstein & Köhler (monoclonal antibodies), and Sanger (protein sequencing & DNA sequencing). The presentation will cover applications of Label-Enhanced SPR in the analysis of proteins, nucleic acids, and small molecules.
We will participate and present a poster on Label-Enhanced SPR at the 5th RSC-BMCS Fragment-based Drug Discovery Meeting in Cambridge, UK, 22-24 March 2015.
We will also spend 25-26 March in the Cambridge area, so if you’re interested in Label-Enhanced SPR and if you’re site is not too far from Cambridge, please contact us and we’ll arrange a meeting!
Please contact us at info@episentum.com for any enquiries.
We have published a series of Technical Notes that are simple how-to guides on the practical implementation of label-enhanced SPR in your lab. If you’re interested in TechNotes, please contact us on sales@episentum.com stating your contact details and research interests, and we will e-mail the requested documents back to you.
Label-Enhanced SPR has already been well established as a powerful tool to improve small molecule analysis on SPR instruments, but now the Label-Enhanced SPR concept has been successfully extended also to improved protein analysis. Details are found in our new Application Note 022 on protein analysis.
Please check out our Application Notes page for more info or order the new document directly from sales@episentum.com.
Our new Application Note 021 demonstrates how label-enhanced SPR expands the measurable kinetic space for fragments and small molecules into previously intractable regions. This provides new unique insights into lead optimization of small molecules and a novel understanding of how the dynamics of interactions involving weakly binding and/or low molecular weight compounds relate to protein function.
Please check out our Application Notes page for more info or order the new document directly from sales@episentec.com.
Episentec (Solna, Sweden) and AstraZeneca (Mölndal, Sweden) have signed a research collaboration agreement regarding the development and implementation of improved methodology for early screening of potential new drug molecules. The research project, aimed at an undisclosed drug target protein, will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the terms of the agreement, AstraZeneca will supply target protein and small molecules for screening, while Episentec will develop and implement new SPR-based screening methodologies. The goal of the project is to develop cost-efficient screening methods with higher sensitivity, higher specificity, and higher throughput than what is possible using today’s state-of-the-art technologies.
Anders Hanning, CEO of Episentec, comments: “We are very happy to get this opportunity to cooperate with AstraZeneca. We really believe that our Label-Enhanced SPR technology has the potential to take today’s SPR-based screening methods to a new level of performance.”
Stefan Geschwindner, Principal Scientist at AstraZeneca, adds: “Entering this collaboration with Episentec will bring us in a position to significantly expand the current application areas of SPR-based drug screening. Having found an experienced partner in that area makes us feel confident in achieving the goals of this collaboration, for the benefit of enabling unprecedented screening approaches as well as unlocking difficult target classes in the near future.”
For further information please contact:
Anders Hanning, CEO, Episentec anders.hanning@episentec.com +46 70 225 99 96
Stefan Geschwindner, Principal Scientist, Discovery Sciences, AstraZeneca R&D Mölndal stefan.geschwindner@astrazeneca.com +46 31 776 2197
About SPR-based drug screening: SPR (Surface Plasmon Resonance) is an optical biosensor method that is commonly used in the screening of potential new drug molecules. SPR is used to detect which molecules that bind to and interact with a specific disease target, usually a protein. SPR drug screening was pioneered by the Swedish company Biacore™, now part of GE Healthcare.
About Episentec: Episentec is a Swedish biotech company established in 2010 by scientists with a comprehensive experience in the development and application of biosensors. The aim of the company is to develop add-on tools that boost the performance of optical biosensor instruments. Episentec’s proprietary concept “Label-Enhanced SPR” substantially improves the performance of SPR-based biosensor instruments and expands their breadth of application. The company markets the Episentec™ range of dye reagents and EpiGrammer™ software for data evaluation, and also offers services for dye labelling of biomolecules and biosensor method development. For more information please visit: www.episentec.com
About AstraZeneca: AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com